ESTRO 2024 - Abstract Book

S2200

Clinical - Upper GI

ESTRO 2024

resection, achieving negative margins (R0). Medically inoperable patients attained a modest median OS of 8 months post-MRgRT.

Conclusion:

MRgRT offers encouraging OS and LC rates with an acceptable toxicity profile in patients with unresectable PDAC, emphasizing its potential across different disease stages. Especially for the subset of metastatic patients with stable disease after exhaustion of first-line chemotherapy, MRgRT is a promising option. Further research and longer-term follow-ups are warranted to consolidate these findings.